
The episode discusses the benefits of Selpercatinib for patients with RET Fusion Positive Early Stage Non-Small Cell Lung Cancer based on early results from the LIBRETTO-432 trial.
Patients with RET Fusion Positive Early Stage Non-Small Cell Lung Cancer Benefit from Selpercatinib: LIBRETTO-432 Early Results An interview with: Jonathan W. Goldman MD, Director of Clinical Trials i
Guests: Jonathan W. Goldman MD, David R Spigel MD
Organizations: ASCO
Products: Selpercatinib
Places: Non-Small Cell Lung Cancer
Explore listener stats, chart rankings, contacts and more on the Audio Journal of Oncology Podcast podcast page.